pharma news today obesity glp-1 🧬 Could this be the future of treatment? Scientists in Germany have developed an experimental “Trojan Horse” weight-loss drug designed to outperform existing therapies like Ozempic and Wegovy. The next-generation treatment GLP-1 Pipeline Update: August 2025

However, in June we observed a shift: among patients with an active supply of AOM tirzepatide, 90.4% had an active supply of the AOM tirzepatide in July, while 8.0% switched to AOM semaglutide

Large-Scale Real-World Analysis In this retrospective cohort study, researchers analysed data from more than 740,000 patients with Type 2 diabetes using the TriNetX Research Network

Mohler technique Whereas the scar runs obliquely across the philtral column in Millard's repair, Mohler modified the technique to create a mirror image of the philtral column on the noncleft side [24]

Additionally, alterations in checkpoint control, such as the loss of cyclindependent kinase (CDK) inhibitors, enable uncontrolled cell cycle progression despite genomic instability, fostering survival under cytotoxic stress and promoting therapeutic resistance, heterogeneity, and relapse [93]

Typically, the first effects you will notice wont necessarily be dramatic drops on the scale, but rather subtle changes like feeling fuller for longer, reduced appetite, and more control over cravings

Le paragraphe suivant passe en revue les diffrentes techniques d'immobilisation